Background Southern Africa has a high incidence of bacterial meningitis in adults, often associated with HIV coinfection. Mortality exceeds 50%, even with appropriate antibiotic therapy, and is not improved with corticosteroids. Glycerol adjuvant therapy reduces long-term morbidity in bacterial meningitis in children, and its use is being promoted. We aimed to assess the eff ectiveness of glycerol as an adjuvant therapy for adults with bacterial meningitis in Africa.
Introduction
Meningitis is a common cause of adult in-patient death in Malawi. The incidence of bacterial meningitis has risen substantially in Malawi, as it has in other southern African countries, since the start of the HIV epidemic. 1 Even with eff ective antibiotics in-patient case fatality exceeds 50%, and up to half of survivors are left with neurological sequelae and disability. 2, 3 Measures to reduce mortality are urgently needed. 1 Corticosteroids, which can be an eff ective adjunctive treatment in settings with a low prevalence of HIV, 4 are not eff ective where most meningitis is HIV-related, including Malawi. 2, 5, 6 Raised intracranial pressure impairs cerebral blood fl ow, and might be a signifi cant contributory factor to mortality and morbidity from all forms of meningitis; therefore, early reduction of intracranial pressure might improve outcome. Glycerol, an orally administered hyperosmolar liquid widely used as a food additive, has been suggested as a promising adjuvant treatment. In children with bacterial meningitis, glycerol reduces neurological sequelae but not case fatality when given either alone or in combination with dexamethasone, 7, 8 although there is some controversy surrounding the design of a Latin American study that found a benefi t for glycerol. 9 Glycerol has previously been used in stroke, head injury, and glaucoma to reduce increased tissue pressure. [10] [11] [12] [13] [14] [15] [16] [17] [18] A meta-analysis of intravenous glycerol in ischaemic stroke suggested that glycerol conferred a short-term advantage, but no benefi t in terms of long-term survival. 19 No trials of glycerol adjuvant therapy in bacterial meningitis have been reported in adults. If the paediatric fi ndings were replicated in adults, glycerol would represent a signifi cant advance in the treatment of bacterial meningitis, particularly in resource-poor settings with a high prevalence of HIV, such as southern Africa, where the burden of disease is high and adjuvant steroid therapy has no clinical advantage.
Glycerol has been used as a food additive and for cosmetic purposes for many years. Toxicity data for oral glycerol indicate that it is safe. Side-eff ects are infrequent, usually mild, and are mostly gastrointestinal in origin. 20, 21 There are rare reports of neurological side-eff ects, such as headache, dizziness, confusion, and amnesia (in elderly patients), 22, 23 and one report of spontaneously reversible hemiparesis in a patient who ingested 500 mL of pure glycerol as a single dose. 24 Glycerol is stable in hot climates, widely available, and inexpensive, and would therefore be ideal for use in resource-poor settings.
Queen Elizabeth Central Hospital (QECH) is a large hospital in Blantyre, Malawi, and serves a catchment population in excess of 1 million people. According to UNAIDS, HIV prevalence in adults in Malawi aged 15-49 years in 2006 was 12%. 25 Admissions to QECH exceed 10000 per year, and 70% of admitted patients are infected with HIV. 26 Meningitis is one of the commonest causes of admission, with Strepto coccus pneumoniae the most common form of bacterial meningitis. 1 Mortality from bacterial meningitis exceeds 50%, and adjunctive steroid therapy in adults does not reduce mortality, so it is not routinely used. 2 We designed a randomised, double-blind, controlled trial to test whether glycerol is an eff ective and safe adjuvant treatment for adults with bacterial meningitis in a setting with high HIV seroprevalence and high mortality from meningitis.
Methods

Patients
The trial started on Sept 10, 2006 , and recruitment was halted on Aug 23, 2008 . There were no facilities for the invasive monitoring of patients at the time of the trial.
Adult patients admitted to the QECH with signs and symptoms of meningitis were screened by clinicians on the wards. All patients had a lumbar puncture and received intravenous ceftriaxone. Patients were then referred to the trial staff for assessment of eligibility. Trial inclusion criteria were clinical suspicion of meningitis (headache, neck pain or stiff ness, reduced level of consciousness, photophobia, confusion, fi ts, rash, or fever) plus cerebrospinal fl uid evidence of bacterial meningitis (>100 white cells per μL with predominant neutrophils or Gram-stain showing bacteria), or cloudy cerebrospinal fl uid if microscopy was delayed (eg, at night). Exclusion criteria were age less than 16 years, cryptococcal meningitis (India ink stain or cryptococcal antigen positive on cerebrospinal fl uid), less than 100 white cells per μL or lymphocytic meningitis, pregnancy, heart failure, and known type-2 diabetes. A capillary whole blood glucose (BM glucose) greater than 12 mmol/L was added as a criterion for exclusion for phase 2 of the study on the advice of the data and safety monitoring board.
Ethics approval was granted by the College of Medicine Research Committee, Malawi, and the Liverpool School of Tropical Medicine, UK. Written informed consent was obtained from all study participants.
Randomisation and masking
A randomisation number list in blocks of 12 was produced by an independent statistician using Stata version 9.0. Numbers and allocation were placed into sealed envelopes. Envelopes were opened sequentially by an independent person not involved in the clinical care or assessment of trial participants, who labelled preprepared containers of glycerol and placebo with a unique study number. Study drug packs were then placed in consecutive order within a secure room. If a patient fulfi lled the study inclusion criteria, verbal and written informed consent was obtained from the patient or, if the patient was unconscious or confused, from the patient's legal guardian. Those unable to read gave witnessed consent. Allocation of the next available study number constituted entering the trial, and analysis was based on study allocation irrespective of subsequent treatment. All envelopes were accounted for. Allocation was masked from clinicians and patients. Treatment with glycerol or placebo was given by trial staff . After the addition of Orange SOBO (a locally produced orange squash) into glycerol and placebo, both liquids were a pale orange colour and were more palatable and indistinguishable in appearance and taste, as assessed by medical and clerical staff within the Department of Medicine, QECH.
Procedures
The study was done in two phases. The fi rst was an openlabel study to assess the ease of giving glycerol and the tolerability of a range of doses by patients to fi nd the highest tolerated dose for use in the second phase-the double-blind, randomised controlled trial.
45 adult patients with symptoms, signs, and cerebrospinal fl uid fi ndings consistent with bacterial meningitis infection who fulfi lled inclusion criteria were recruited. After consent was obtained, 15 patients each received 50 mL, 75 mL, or 100 mL of glycerol four times a day for 4 days. Paediatric studies used 6 mL/kg per day: 8 this corresponded to 300-360 mL glycerol daily for the average Malawian weighing 50-60 kg. Glycerol was diluted with water at a ratio of 5:4 so that the consistency was indistinguishable from that of 50% sugar solution (the proposed placebo for phase 2). Patients therefore received diluted glycerol 90 mL, 135 mL, or 180 mL four times a day. Clinical details of all cases, including possible or probable adverse events due to glycerol, were recorded.
The second phase of the study was the main trial, in which patients were randomly assigned to receive the highest tolerated dose of glycerol or equivalent volume of placebo. All patients with probable meningitis were treated with intravenous ceftriaxone twice a day for at least 10 days, or until treatment was changed according to the results of culture and sensitivity testing. If cryptococcal infection was diagnosed after recruitment to the study, patients were treated with oral fl uconazole (in accordance with national guidelines), and the study drug was discontinued.
Those not enrolled in the study received standard care in accordance with national guidelines.
Glycerol or placebo was given orally or via nasogastric tube immediately after enrolment at a dose of 135 mL (75 mg glycerol mixed with water or 135 mL 50% sugar solution) four times a day for 4 days (16 doses). This was the highest tolerated dose in the dose-fi nding study. The dose was repeated after antiemetics if vomiting occurred within 30 min of administration. A nasogastric tube was routinely inserted in those with a score on the Glasgow coma scale (GCS) of less than 8, or in any patient unable to swallow for any other reason. Position of the tube was checked daily by auscultating over the epigastrium while injecting air through the nasogastric tube and by ensuring that tube aspirate was acidic (turned blue litmus paper pink).
After 48 h or at least eight doses of glycerol therapy, a second lumbar puncture was done. After 10 days of antibiotic therapy a full neurological examination including hearing assessment was done. Hearing tests were done with a Kamplex Diagnostic Audiometer AD12. All patients were treated in hospital for at least 10 days, with daily clinical assessment. Patients alive at discharge were asked to return at day 40 for follow-up assessment; those who did not attend were traced at home. At day 40, patients had a full neurological examination including hearing assessment using audiometry, and the Glasgow outcome scale was used as a measure of neurological disability.
The primary endpoint was death by day 40. Secondary endpoints were death or disability (Glasgow outcome score-disabled and partially or completely dependent) by day 40;
27 death by day 10; hearing loss in those not dead or disabled by day 40; time to death; cerebrospinal fl uid opening pressure 2 days after treatment; and serious adverse events (SAEs). A-priori subgroup analyses included patients with proven or probable bacterial meningitis alone and proven pneumococcal meningitis.
Adverse events and SAEs were recorded. SAEs were classifi ed as defi nitely, possibly, or probably related to study drug, as defi ned by the International Conference on Harmonisation Guidelines.
All patients were tested for HIV. Consent with appropriate counselling was sought at recruitment to the study, or retrospectively after recovery for those initially unconscious or confused. Patients' guardians were aware that HIV testing would be done, but they were not informed of results. Relatives and guardians were encouraged to attend for voluntary HIV testing, regardless of patients' results.
Patients were counselled about their results before discharge from hospital. Those found to be HIV positive were started on cotrimoxazole prophylaxis and referred to the antiretroviral therapy clinic.
Cerebrospinal fl uid and blood for culture were analysed by the Malawi-Liverpool-Wellcome Trust (MLW) laboratory. Cerebrospinal fl uid was processed by use of standard laboratory techniques for cell count, diff erential white-cell count (when >20 cells per μL present) and Gram stain. Cerebrospinal fl uid was cultured on sheep blood and chocolate agar for 48 h and subcultured for 50 mL glycerol four times a day (n=15) 75 mL glycerol four times a day (n=15) 100 mL glycerol four times a day (n=15) identifi cation as appropriate. Blood was cultured with the BacT alert system. Organisms were identifi ed by use of conventional culture-based microbiological techniques. Cerebrospinal fl uid cryptococcal antigen agglutination tests (Pastorex Crypto Plus Biorad, Marnes-la-Coquette, France) were done by the MLW laboratory on a subset of patients. Blood for malaria fi lm, full blood count, and biochemistry was analysed by the QECH laboratory. HIV serological testing was done in duplicate for every patient by use of Uni-Gold Recombigen HIV rapid test (Trinity Biotech, Wicklow, Ireland) and Determine HIV-1/2 (Abbott, USA). BM glucose was measured with Glucostix (Bayer Diagnostics, Basingstoke, UK) at least twice a day while the patient was taking study drug.
Statistical analysis
The sample size required to detect a reduction in mortality from 56% (previous mortality in observational studies) to 40%, with α=0·05 and β=0·9, was 216 patients per group (calculated using Stata 8.0). Data were double entered into Microsoft Access and verifi ed before being analysed with Stata 8.0. The analytical plan was fi nalised before unmasking.
All patients were analysed for the primary outcome excluding those who were lost to follow-up. A per-protocol analysis (restricted to those not withdrawn from glycerol or placebo for reasons other than death) was also planned for the mortality-defi ned end-points. Logistic regression was used to construct a model to estimate the primary and secondary outcomes (with the exception of hearing loss and cerebrospinal fl uid opening pressure at 2 days), and odds ratios (ORs) calculated unadjusted and adjusted for the following prespecifi ed potential confounding factors: HIV serostatus, antiretroviral use, prior AIDS-defi ning illness (modifi ed WHO grades 3 or 4 ), 28 age, sex, prior antibiotic use, score on the GCS on admission, fi ts before admission, duration of symptoms, pretreatment with antibiotics, and organism isolated from cerebrospinal fl uid or blood. The secondary analysis of time to death was analysed with Cox's proportional hazard ratios, unstratifi ed and stratifi ed by the same potential confounding factors. Statistical signifi cance for the primary outcome was defi ned as p less than 0·05.
An unblinded interim analysis by the data safety monitoring board had been prespecifi ed after 100 deaths. Indicative criteria for stopping included recruitment to be halted if a treatment group showed evidence of harm exceeding conventional levels of chance alone (p<0·01), and recruitment to be halted if there was clear evidence of benefi t with a signifi cance level of p less than 0·001.
The trial is registered with controlled-trials.com, number ISRCTN70121840.
Role of the funding source
The sponsor had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The dose-fi nding study ran from March, 2006, to July, 2006. 45 patients were randomly assigned to receive one of three doses of glycerol (table 1) . About 50% of patients in each group experienced nausea, vomiting, or diarrhoea. Vomiting did not occur in any patient receiving glycerol via nasogastric tube. No clear relation existed between the dose of glycerol and frequency of sideeff ects. 14 (31%) patients had transiently increased blood glucose concentrations greater than 12·2 mmol/L after taking study drug. Peak hyperglycaemia ranged from 12·2-20·4 mmol/L. One patient had a single reading of 40 mmol/L at recruitment, but died before receiving study drug. No patients needed treatment with insulin. Five patients had hyperglycaemia (12·2-20·4 mmol/L) after glycerol had been discontinued, suggesting type 2 diabetes or a stress response was the cause. Patients had diffi culty swallowing the largest volume given. Eight of 15 patients in the 50 mL group, seven of 15 in the 75 mL group, and ten of 15 in the 100 mL group died in hospital. On the basis of tolerability, the 75 mL dose was used for the subsequent trial.
The trial started on Sept 10, 2006, and recruitment was halted on Aug 23, 2008 . 3716 patients were screened, 380 met the inclusion criteria, and 265 were randomly assigned to placebo or glycerol (fi gure 1). Baseline characteristics of the two groups were similar (table 2) . Follow-up of survivors to day 40 was 98% and 99% in the placebo and glycerol groups, respectively.
The study was stopped following the planned interim analysis after 100 deaths, with 7 months of the trial still to run and 61% of the predetermined recruitment completed. The data safety monitoring board advised stopping recruitment on the grounds of futility. Patients already recruited to the trial were followed up until completion of follow-up or the primary endpoint was reached. 40 days after enrolment, the proportion of patients who died was signifi cantly larger in the glycerol group than in the placebo group; this was the same for death and disability. Overall, 61 (49%) of 125 patients in the placebo group and 86 (63%) of 136 in the glycerol group died by day 40 (odds ratio [OR] 1·8, 95% CI 1·1-3·0; p=0·02). The OR adjusted for prespecifi ed potential confounding factors was 2·4 (95%CI 1·3-4·2, p=0·003). Glycerol did not improve death and disability by day 40, or death at day 40 in proven bacterial disease or pneumococcal disease (table 3) . Among survivors tested by audiometry, 14 of 41 patients in the placebo group and four of 31 patients in the glycerol group were deaf at day 40 (p=0·02). Time to death is shown in fi gure 2. The unadjusted hazard ratio (HR) for death was 1·7 (95% CI 1·2-2·4), and the adjusted HR was 2·0 (95% CI 1·4-2·9), with glycerol seeming to be detrimental.
138 (52%) of 265 patients had a second lumbar puncture. The median opening pressure of cerebrospinal fl uid 2 days after randomisation was 15 cm CSF (IQR 9-21) in the placebo group, and 11·5 cm CSF (IQR 6-19) in the glycerol group (Willcoxon rank sum diff erence p=0·08). Median BM glucose on day 2 in both groups was 6 mmol/L (range 4-11 mmol/L).
There were two deaths thought possibly to be due to study drug in view of the rapid and unexpected deterioration in the patients' clinical condition. A 70-year-old HIV-positive woman was admitted with 1 week's history of headache, fever, and confusion, and on admission had a GCS score of 13. She was assigned glycerol. Her level of consciousness improved, but on day 2 she developed seizures refractory to anticonvulsant therapy and she became hypertensive (170/90 mmHg from a baseline of 120/80 mmHg). Salmonella typhimurium was cultured from cerebrospinal fl uid. A second lumbar puncture was not done, and the study drug was discontinued on day 3. She died on day 12. The second case was a 35-year-old HIV-positive woman with a 1-day history of illness and a GCS score of 12 on admission. She was assigned placebo. She improved rapidly to GCS score of 15 by day 2. Streptococcus pneumoniae was cultured from blood and cerebrospinal fl uid. Discharge was planned on day 10 when she developed generalised weakness and vomiting without fever. She maintained a normal blood pressure and good urine output. On day 11 her level of consciousness fell (GCS 6), although no focal neurological defi cit was identifi ed. She died on day 13. The most likely diagnosis for both patients was, on clinical criteria, a major cerebrovascular event secondary to meningitis. However, a brain scan was not possible in either case in this setting.
Glycerol was well tolerated compared with placebo. 79 (65%) of 121 patients who were conscious and able to communicate had gastrointestinal adverse events (nausea, vomiting, diarrhoea) in the placebo group, compared with 85 (66%) of 129 patients who were conscious and able to communicate in the glycerol group. Seizure during the initial 10 days after randomisation occurred in 37 (31%) of 121 patients in the placebo group and 64 (50%) of 129 in the glycerol group (p=0·002); 
Discussion
In our study in adults, which was stopped early by the data safety monitoring board due to futility, glycerol was associated with signifi cantly higher mortality within 40 days than was placebo. Glycerol was also associated with worse outcomes in all major secondary analyses, except deafness, at day 40. This trial therefore does not support the use of glycerol as adjunctive treatment for bacterial meningitis in adults in Malawi. These fi ndings from the fi rst adult study of glycerol are markedly diff erent from those of studies in children (panel). In a small study of infants and children in Finland, oral glycerol reduced severe or profound hearing loss. 7 A larger multicentre paediatric study in Latin America 8 suggested that glycerol prevented neurological sequelae, although several methodological concerns were subsequently raised about this study. 9 A small, randomised, double-blind study in India by Sankar and colleagues 30 comparing dexamethasone and oral glycerol adjuvant therapies in children with acute bacterial meningitis did not fi nd any signifi cant diff erence in hearing loss and neurological sequelae between the groups. 31 Animal models of pneumococcal meningitis have not shown a benefi cial eff ect from glycerol. 32 Our fi ndings suggest glycerol confers no benefi t and might be harmful. However, there are major diff erences in our study population and those of other studies: our patients were adults, 84% were HIV positive, and glycerol was given for 4 days rather than 2 days. HIV serostatus was not reported in the paediatric studies, although it is highly likely that most participants were HIV negative. Additionally, access to health care is often delayed in sub-Saharan Africa compared with other settings; most of our patients had symptoms for 5 days or more, compared with over 85% presenting within 48 h of the onset of symptoms in previous studies. Despite these population diff erences, why glycerol seemed harmful is hard to explain. Hyperglycaemiawhich adversely aff ects outcome compared with normoglycaemia after stroke, acute myocardial infarct, pneumonia, and in those acutely ill on intensive care [33] [34] [35] [36] [37] -is not a plausible explanation, because it was rarely detected in either of the treatment groups in our study. One possibility is that the sugar solution used as placebo for blinding was benefi cial, but this seems unlikely; there was no evidence of hypoglycaemia in any patient before giving the study drug.
That a higher proportion of patients had convulsions in the glycerol group than in the placebo group is concerning, and might relate to the poor outcome. This could be a coincidental fi nding associated with the severely ill population in this study, or could be directly related to an eff ect of glycerol. This has not been previously documented in humans. A study in mice found that oral glycerol could produce changes in behaviour and seizures within 30 min. 38 The exact cause of these eff ects was not clear, but an increase in oxygen species might be the cause, and the eff ects were associated with increased interleukin 1β concentrations in the hippocampus. In human studies, rebound phenomena can occur with osmotherapy, particularly mannitol, 39 but evidence for its occurrence with glycerol therapy is mixed. Some studies do not show a rebound increase in intracranial pressure with either oral or intravenous glycerol (compared with mannitol), 15, 39, 40 others show substantial rises in intracranial pressure with continuous intravenous and intermittent oral administration. 41, 42 Rebound increase of intracranial pressure might be attributable to a reversal of the concentration gradient of the osmotic agent between blood and cerebrospinal fl uid (or brain interstitial fl uid) as the drug is eliminated. 41 Although this increase in pressure is not generally thought to be clinically signifi cant, its relevance is unclear in the context of bacterial meningitis. Reliable clinical interpretation of the changes in cerebrospinal fl uid opening pressures is diffi cult, in part because of early mortality.
There are potential limitations to this study. Although this hospital is better staff ed and supported than many in a similar setting, general medical care is suboptimal compared with that off ered in developed countries. Additionally, there was limited intensive or high dependency care available for such critically ill patients with severe sepsis. Overall, this is a typical southern
Panel: Research in context
Systematic review
We searched PubMed using the terms "glycerol", "adjuvant therapy", and "bacterial meningitis". There are no randomised controlled trials using glycerol adjuvant therapy in meningitis in adults. There is one trial in children in Latin America where adjuvant dexamethasone or glycerol with placebo was administered. Glycerol did not improve mortality or deafness, but did reduce severe n eurological sequelae. Hearing loss was reduced in a small study in children in Finland, but no advantage was seen from glycerol in another small paediatric study in India.
Interpretation
Our trial is in adults, most of whom were HIV positive, and showed evidence of increased mortality with glycerol. It therefore makes it unlikely that glycerol is benefi cial in adults or in those who are HIV positive, but does not exclude the possibility of benefi t in children.
African hospital, and the population of patients and trial setting is likely to be representative of other sub-Saharan African settings with a high prevalence of HIV. The results do not exclude the possibility that glycerol might be eff ective in a setting with low HIV prevalence in which patients present earlier and where HIV infection is less common. Residual confounding is a possibility, but the fi nding is highly statistically signifi cant, no subgroup analysis suggested benefi t, and adjusting for identifi ed confounding factors only strengthened the association, making residual confounding unlikely. The mortality diff erence seen at interim analysis by the data safety monitoring board strengthened with follow-up of enrolled patients, and the adverse eff ect persisted after adjusting for confounding, thus supporting the decision to stop early.
In adults in Malawi or other resource-poor regions where bacterial meningitis presents late and commonly occurs in people who are infected with HIV, glycerol cannot be recommended as adjunctive therapy. Other ways of reducing the substantial mortality associated with this disease need to be explored. Glycerol might be harmful as adjunctive therapy in adults with bacterial meningitis in sub-Saharan African settings with a high prevalence of HIV.
